AnteBC assesses a woman’s personalized risk of developing breast cancer and gives clinical recommendations for further action.
Breast cancer is the most common cancer in women. Advances in cancer genetics make it possible to identify women at increased risk for breast cancer in order to provide them with timely examinations and personalized follow-up plan. We use the polygenic risk score (PRS) methodology for analysis and resulting clinical report has been developed by oncologists.
AnteBC is a registered in vitro diagnostic device (IVD medical device) and it has been developed by the healthcare service provider Antegenes (License: L04685).
What does AnteBC test include?
- Analyzes of 2803 genetic variants associated with breast cancer;
- Individual polygenic risk score for breast cancer;
- The individual risk of breast cancer compared to the rest of the female population;
- Likelihood to get breast cancer in 10 years and risk assessment compared to a woman with average genetic risk;
- Interpretation of the test results with clinical recommendations;
- Genetic counseling.
Who can benefit from AnteBC test?
AnteBC test is recommended for:
- Women between the ages of 30-75 of European origin (Note: Genetic risk studies used by AnteBC have been conducted in populations of European descent).
The AnteBC test is not recommended if any of the following significant changes affect risk:
- The patient has been diagnosed with atypical breast hyperplasia or in situ carcinoma;
- A high risk monogenic mutation significantly increasing the risk of breast cancer has been identified in the patient or the biological relatives of the patient, for example: BRCA1, BRCA2, CHEK2, PALB2, ATM, TP53, CDH1, STK11, and other genes.
What is needed for AnteBC testing?
AnteBC testing requires the patient’s DNA, which is collected and isolated from the buccal swab sample (cells inside the cheek are collected with a special cotton swab).
How long does it take to get AnteBC test results?
Test results are available within 6 weeks from the sample being received by Antegenes.
AnteBC Test Limitations
- AnteBC test is not used to diagnose breast cancer.
- AnteBC test is not validated for use by individuals of non-European descent.
- An elevated risk estimated by the AnteBC test does not mean that the patient will develop breast cancer during their lifetime. Also, a moderate or lower risk does not mean that the patient will not develop the disease.
- AnteBC test is patient-specific and does not assess the risk of the patient’s family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
- AnteBC test does not analyze rare pathogenic mutations in genes that significantly increase the risk of breast cancer, such as BRCA1, BRCA2, CHEK2, PALB2, ATM, TP53, CDH1, STK11, and others.
- The AnteBC test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
- Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
- The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of breast cancer.